Person:
ŞİMŞEK, MELİH

Loading...
Profile Picture
Status
Organizational Units
Organizational Unit
Job Title
First Name
MELİH
Last Name
ŞİMŞEK
Name
Email Address
Birth Date

Search Results

Now showing 1 - 10 of 18
  • PublicationMetadata only
    Evaluation of 22 Primary Gastrointestinal Lymphoma Patients
    (2019-02-01T00:00:00Z) Yildirim, Nilgun; Turkeli, Mehmet; Akdemir, Mehmet Naci; Simsek, MELİH; TEKİN, Salim Başol; ŞİMŞEK, MELİH
    Objective: Primary gastrointestinal non-hodgkin lymphomas (PGI-NHL) are uncommon diseases with treatment modalities including chemotherapy, surgery, and radiotherapy. Our aim is to analyze the demographic and clinical features and treatment results of PGI-NHL.
  • PublicationMetadata only
    Are We Late in the Diagnosis of Malignities Occurring in Solid Organ Transplant Patients? 11 Years- Experience
    (2016-02-01T00:00:00Z) Turkeli, Mehmet; Simsek, MELİH; Aldemir, Mehmet Naci; Yildirim, Nilgun; ÇANKAYA, Erdem; ERDEMCİ, Burak; BİLİCİ, Mehmet; TEKİN, Salim Başol; Arslan, Sukru; KORKUT, Ercan; ŞİMŞEK, MELİH
    Objective: Our aim is to evaluate the frequency and characteristics of cancer in the population of patients with solid organ transplant who are under immunosuppressive medication. In this study we aimed to emphasize the importance of early diagnosis of cancer in solid organ transplant recipients. An aging population began to receive solid organ transplantation and survival times prolonged. But this had a cost and new problems came forward. Especially de novo cancers because of immunosuppressive therapy took notice. Risk of malignancy increases after organ transplantation and cancer incidence was about 2.3-3.1% in these patients including skin cancer, lung cancer, malign lymphoma, cervix cancer, kaposi sarcoma, and hepatobiliary cancer.
  • PublicationMetadata only
    Relationship between 18-FDG-PET/CT and Clinicopathological Features and Pathological Responses in Patients with Locally Advanced Breast Cancers
    (2019-06-01T00:00:00Z) Yildirim, Nilgun; Simsek, MELİH; Aldemir, Mehmet Naci; BİLİCİ, Mehmet; TEKİN, Salim Başol; ŞİMŞEK, MELİH
    Objective: We investigated the relationship between the maximum standardized uptake value (SUVmax) of whole-body positron emission tomography/computed tomography (PET/CT) performed before treatment and the demographical and histopathological features in locally advanced breast cancer (LABC), as well as the role of PET/CT in the evaluation of pathological complete response (pCR) after neoadjuvant chemotherapy (NAC).
  • PublicationMetadata only
    Immunological Agents Used in Cancer Treatment
    (2019-02-01T00:00:00Z) Simsek, MELİH; TEKİN, Salim Başol; BİLİCİ, Mehmet; ŞİMŞEK, MELİH
    Immune checkpoint inhibitors (ICI) are monoclonal antibodies targeting cytotoxic T lymphocyte antigen-4 (CTLA-4), programmed cell death protein-1 (PD-1), or PD-1 ligand (PD-L1). ICI are approved for the treatment of malign melanoma, non-small cell lung cancer, classical Hodgkin lymphoma, head and neck squamous cell carcinoma, urothelial carcinoma, and renal cell carcinoma. They can lead to long-term anti-tumor responses by deactivating the brake mechanism in the immune system. Ipilimumab, tremelimumab, pembrolizumab, nivolumab, atezolizumab, durvalumab, and avelumab are examples of ICI. CTLA-4 is a brake mechanism in immune response. Ipilimumab and tremelimumab are antibodies against CTLA-4. PD-1 is another important immune checkpoint co-inhibitor receptor that is expressed by activated T cells in the peripheral tissue. As a result of blockage of the PD-1/PD-L1 pathway, local tumor-specific immune response augments, and long-term tumor control can be achieved. In recent years, ICI are approved for the treatment of various malignities. They may be responsible for specific toxicities called immune-related adverse events (irAEs). irAEs are a consequence infiltration of normal tissues by activated T lymphocytes that are responsible for autoimmunity. Corticosteroids and anti-tumor necrosis factor agents, such as infliximab and mycophenolate mofetil, are effective in the treatment of irAEs. Immune checkpoint inhibition with monoclonal antibodies against CTLA-4 and/or PD-1/PD-L1 by single agent or combination treatments became a new option in various solid tumors. However, ICI have unique adverse events, and these adverse events should be considered in any new onset clinical situation and should be managed properly. Future prospective randomized clinical trials will clarify recent questions.
  • PublicationMetadata only
    Mide kanserli hastaların demografik özelliklerinin sağ kalıma etkisi
    (2022-05-01T00:00:00Z) Karadeniz, Andaç; Bilici, Mehmet; Şimşek, Melih; ŞİMŞEK, MELİH
  • PublicationMetadata only
    The effect of adenosine triphosphate on sunitinib-induced cardiac injury in rats
    (2020-08-01T00:00:00Z) KARA, ALİ VEYSEL; Aldemir, Mehmet Şerif; Simsek, MELİH; ÖZÇİÇEK, FATİH; MAMMADOV, RENAD; YAZICI, GÜLCE NAZ; SUNAR, MUKADDER; COŞKUN, REŞİT; GÜLABOĞLU, Mine; SÜLEYMAN, HALİS; ŞİMŞEK, MELİH
    In this study, we aimed to show the effect of adenosine 5 --triphosphate (ATP) on sunitinib-induced cardiac injury in rats. The rats (n = 30) were divided equally into three groups as sunitinib group (SG), sunitinib plus ATP group (SAG), and healthy group (HG); 2 mg/kg ATP was injected intraperitoneally (ip) to the SAG group. Same volume normal saline as solvent was administered ip to the other two groups. After 1 h, 25 mg/kg sunitinib was applied orally via catheter to stomach in the SAG and SG groups. This procedure was repeated once daily for 5 weeks. At the end of this period, all animals were sacrificed and their cardiac tissue was removed. Malondialdehyde (MDA), total glutathione (tGSH), tumor necrosis factor alpha (TNF-alpha), and nuclear factor kappa B (NF-kappa B) levels in rats- cardiac tissues and troponin I (Tp-I) levels in rats- blood samples were evaluated. Histopathological analysis was also performed in cardiac tissues of the animals. MDA, TNF-alpha, NF-kappa B, and Tp-I levels were higher in the SG group compared to the SAG and HG groups (p < 0.001). tGSH levels of the SG group were lower than the SAG and HG groups (p < 0.001). The structure and morphology of cardiac muscle fibers and blood vessels were normal in the control group. In the SG group, obvious cardiac muscle tissue damage with dilated myofibers, locally atrophic myofibers, and congested blood vessels were observed. In the SAG group, marked amelioration in these findings was observed. We showed this for the first time that ATP administration exerts a protective effect against cardiac effects of sunitinib.
  • PublicationMetadata only
    Efficacy and tolerability of weekly docetaxel, cisplatin, and 5-fluorouracil for locally advanced or metastatic gastric cancer patients with ECOG performance scores of 1 and 2.
    (2015-01-01T00:00:00Z) Turkeli, Mehmet; Aldemir, Mehmet Naci; Cayir, Kerim; Simsek, MELİH; Bilici, Mehmet; Tekin, Salim Basol; Yildirim, Nilgun; Bilen, Nurhan; Makas, Ibrahim; ŞİMŞEK, MELİH
  • PublicationMetadata only
    Metastatic Breast Carcinoma Mimicking Urothelial Carcinoma
    (2022-06-01T00:00:00Z) Shbair, Abdallah T. M.; YASİN, Ayşe İrem; TOPÇU, Atakan; ÇOBAN, GANİME; UZUNOĞLU, GÖKÇE DENİZ; ŞİMŞEK, MELİH; YASİN, AYŞE İREM; TOPÇU, ATAKAN; ÇOBAN, GANİME; UZUNOĞLU, GÖKÇE DENİZ; ŞİMŞEK, MELİH
    Besides being the most frequently diagnosed cancer in women, breast cancer is the main cause of cancer-related deaths in this group of patients. Breast cancer frequently metastasizes to bone, lung, brain, and liver. Renal metastasis from the breast is extremely rare. Here we aimed to report a case of breast cancer with metastasis to bone and left renal pelvis. A 58-year old woman with a mass lesion in the left renal pelvis that mimicked urothelial carcinoma was referred to our clinic. The left nephroureterectomy procedure was performed, and the pathology revealed that a renal pelvis metastasis secondary to breast cancer.
  • PublicationMetadata only
    A case report of fulminant hepatitis due to ribociclib with confirmed by liver biopsy in breast cancer
    (2021-06-01T00:00:00Z) TOPÇU, Atakan; YASİN, Ayşe İrem; SHBAIR, ABDALLAH T.M.; BEŞİROĞLU, MEHMET; ŞİMŞEK, MELİH; SUCUOĞLU İŞLEYEN, ZEHRA; YURTSEVER, İSMAİL; GÜCİN, ZÜHAL; ŞEKER, Mesut; TÜRK, HACI MEHMET; TOPÇU, ATAKAN; YASİN, AYŞE İREM; SHBAIR, ABDALLAH T.M.; BEŞİROĞLU, MEHMET; ŞİMŞEK, MELİH; SUCUOĞLU İŞLEYEN, ZEHRA; YURTSEVER, İSMAİL; GÜCİN, ZÜHAL; ŞEKER, MESUT; TÜRK, HACI MEHMET
    Introduction Breast cancer is the most frequently diagnosed cancer in women worldwide. Ribociclib is now frequently used in the treatment of metastatic hormone-positive and human epidermal growth factor receptor 2 (HER 2)-negative breast cancer. Case Report A 54-year-old woman with breast cancer presented at a clinic in November 2017 with multiple lung and bone metastases. After receiving multiple lines of treatment due to disease progression, ribociclib and fulvestrant were initiated. Grade 4 toxicity was observed due to ribociclib during follow-up, and ribociclib was discontinued permanently. Management & Outcome: Given that liver transaminases and bilirubin elevation persisted despite discontinuation of the treatment, other reasons for liver toxicity were investigated. Abdominal MRI showed no liver metastases, although there was acute hepatitis. A liver biopsy was performed to determine the etiology. The pathology result was compatible with drug-induced acute fulminant toxic hepatitis. After liver biopsy, prednisolone treatment was initiated, after which the laboratory findings normalized. Discussion Although there are reported cases showing improvement in liver enzymes after ribociclib discontinuation, in our case, no recovery from hepatotoxicity was noticed. The treatment was changed to another hormonal pathway therapy option, exemestane. To the best of our knowledge, this is the first case in the literature reporting this rare side effect of ribociclib, which is a liver biopsy-proven fulminant hepatitis.
  • PublicationMetadata only
    The importance of the glucose-to-lymphocyte ratio in patients with hepatocellular carcinoma treated with sorafenib
    (2021-08-01T00:00:00Z) YILMAZ, Ali; ŞİMŞEK, MELİH; HANNARİCİ, Zekeriya; Buyukbayram, Mehmet E.; BİLİCİ, Mehmet; Tekin, Salim B.; ŞİMŞEK, MELİH
    Aim: To show the prognostic significance of the glucose-to-lymphocyte ratio (GLR) in hepatocellular carcinoma (HCC). Patients & methods: A total of 150 patients with advanced HCC who were treated with sorafenib in our center between January 2011 and December 2019 were included in the study retrospectively. Neutrophil-to-lymphocyte ratio, systemic immune-inflammation index, lymphocyte-to-monocyte ratio, platelet-to-lymphocyte ratio, prognostic nutritional index and GLR were analyzed to assess their prognostic value using Kaplan-Meier and Cox regression analysis before and after propensity score matching (PSM). Results: In univariate analysis before and after PSM, albumin-bilirubin grade, neutrophil-to-lymphocyte ratio, systemic immune-inflammation index, lymphocyte-to-monocyte ratio, prognostic nutritional index, AFP level and GLR were found to be significantly associated with both progression-free and overall survival. In multivariate analysis before and after PSM, GLR, albumin-bilirubin grade and AFP were determined to be independent prognostic factors for progression-free and overall survival. Conclusion: The GLR prior to sorafenib treatment is a new prognostic biomarker that may predict survival in advanced HCC.